[Proceedings: Is hemorrhage in early pregnancy and its drug therapy an increased risk of teratogenesis?].
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000033:Abortion, Threatened / Q000188:drug therapy*; D000498:Allyl Compounds / Q000009:adverse effects; D000632:Aminopyrine / Q000009:adverse effects; D002707:Chlordiazepoxide / Q000009:adverse effects; D002746:Chlorpromazine / Q000009:adverse effects; D004962:Estranes / Q000009:adverse effects; D005260:Female; D006801:Humans; D006914:Hydroxysteroids / Q000009:adverse effects; D008795:Metronidazole / Q000009:adverse effects; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011374:Progesterone / Q000009:adverse effects; D011372:Progestins / Q000009:adverse effects; D012383:Romania; D013267:Stilbenes / Q000009:adverse effects; D014592:Uterine Hemorrhage / Q000188:drug therapy*
D000498:Allyl Compounds; D004962:Estranes; D006914:Hydroxysteroids; D011372:Progestins; D013267:Stilbenes; D000632:Aminopyrine; D008795:Metronidazole; D011374:Progesterone; D002707:Chlordiazepoxide; D002746:Chlorpromazine
Stellt die Blutung in der Frühschwangerschaft und ihre medikamentöse Behandlung ein erhöhtes teratogenetisches Risiko dar.